Jack W. Schuler Acquires 51,181 Shares of Accelerate Diagnostics, Inc. (AXDX) Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler purchased 51,181 shares of Accelerate Diagnostics stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average price of $18.67 per share, for a total transaction of $955,549.27. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) opened at $20.75 on Thursday. Accelerate Diagnostics, Inc. has a 52-week low of $16.75 and a 52-week high of $30.45.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/11/16/jack-w-schuler-acquires-51181-shares-of-accelerate-diagnostics-inc-axdx-stock.html.

A number of institutional investors have recently modified their holdings of AXDX. American International Group Inc. boosted its position in Accelerate Diagnostics by 7.1% in the first quarter. American International Group Inc. now owns 14,187 shares of the medical research company’s stock valued at $343,000 after buying an additional 939 shares in the last quarter. FMR LLC acquired a new stake in Accelerate Diagnostics in the first quarter valued at approximately $7,260,000. Teachers Advisors LLC boosted its position in Accelerate Diagnostics by 2.9% in the first quarter. Teachers Advisors LLC now owns 39,105 shares of the medical research company’s stock valued at $946,000 after buying an additional 1,087 shares in the last quarter. Legal & General Group Plc boosted its position in Accelerate Diagnostics by 0.3% in the first quarter. Legal & General Group Plc now owns 5,123 shares of the medical research company’s stock valued at $123,000 after buying an additional 15 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Accelerate Diagnostics by 10.3% in the first quarter. Vanguard Group Inc. now owns 1,159,421 shares of the medical research company’s stock valued at $28,058,000 after buying an additional 107,977 shares in the last quarter. Hedge funds and other institutional investors own 44.44% of the company’s stock.

AXDX has been the topic of a number of research analyst reports. BidaskClub lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Finally, ValuEngine lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Three investment analysts have rated the stock with a sell rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $33.00.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply